IDEXX Laboratories stock (US45168D1046): Double-digit jump after strong earnings and Nasdaq 100 outperformance

IDEXX Laboratories shares have rallied strongly on Nasdaq after beating quarterly earnings expectations and posting double?digit revenue growth in its core companion animal diagnostics business. What is behind the move, and how does the pet health specialist make its money?

IDEXX Laboratories stock has been among the stronger movers in the Nasdaq 100 lately, with the shares recently trading around the high-$570s after a more than 3% daily gain, according to data from Nasdaq market statistics as referenced by Business Insider on 06/09/2026.Business Insider as of 06/09/2026 The renewed momentum follows a solid quarterly earnings report in which the veterinary diagnostics group exceeded Wall Street profit expectations and delivered double?digit revenue growth in its key companion animal segment, as highlighted by recent analyst summary data.MarketBeat as of 06/05/2026

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories
• Sector/industry: Veterinary diagnostics and animal health technology
• Headquarters/country: Westbrook, Maine, United States
• Core markets: Global companion animal veterinary practices, livestock and poultry producers, water testing labs
• Key revenue drivers: Companion animal diagnostic tests, in?clinic analyzers, reference lab services, recurring consumables and software subscriptions
• Home exchange/listing venue: Nasdaq Global Select Market (ticker: IDXX)
• Trading currency: US?Dollar (USD)

IDEXX Laboratories: core business model

IDEXX Laboratories focuses on diagnostic solutions and software for veterinary clinics, livestock producers and water quality monitoring, with a heavy emphasis on companion animals such as dogs and cats.IDEXX company information as of 03/2026 The company develops and sells in?clinic analyzers, rapid test kits and access to central reference laboratories, allowing veterinarians to run blood, chemistry and specialty tests to support preventive care and medical decision?making for pets.

A cornerstone of the business model is the sale of instruments that are then followed by a high?margin stream of recurring consumables and testing services over the life of the installed base.IDEXX investor overview as of 02/2026 Once veterinary practices adopt an IDEXX analyzer platform, they typically continue to purchase IDEXX?branded test kits and send diagnostic samples to the company’s labs, which can generate revenue for many years and supports strong customer retention.

Beyond hardware and testing, IDEXX has built a portfolio of practice management software and cloud?based tools designed to streamline workflows in veterinary clinics, including patient records, appointment scheduling and billing functions.IDEXX software overview as of 01/2026 These digital solutions are typically sold on subscription models, adding another recurring element to revenue and helping integrate diagnostic data directly into the clinic’s IT systems.

Main revenue and product drivers for IDEXX Laboratories

According to the company’s latest annual reporting, companion animal diagnostics – including consumables for in?clinic instruments and reference laboratory testing services – remains the largest contributor to IDEXX’s revenue mix, accounting for the majority of total sales in 2024, as outlined in the company’s Form 10?K filed in early 2025.IDEXX Form 10?K as of 02/2025 Growth in this segment has been supported by higher testing volumes per clinic and expansion of the global installed base of analyzers.

In its most recent quarterly update, IDEXX reported double?digit year?over?year revenue growth in its companion animal group, alongside stronger?than?expected earnings per share of roughly the mid?$3 range, surpassing consensus estimates, according to data compiled by MarketBeat.MarketBeat as of 05/02/2026 Management highlighted higher diagnostic testing frequency and continued uptake of its premium test panels as key growth drivers for the quarter.

Outside of companion animals, IDEXX generates additional revenue from its water quality testing business, which supplies tests for detecting microbiological contamination in municipal and industrial water systems, and from livestock, poultry and dairy diagnostic products aimed at herd health and food safety monitoring.IDEXX water division overview as of 11/2025 These segments tend to grow more steadily and provide diversification but are smaller than the pet?focused portfolio.

For investors, another important revenue lever is pricing and product mix, as IDEXX continues to introduce new high?value tests, expand panels for chronic disease monitoring and add integrated software features that can support higher average revenue per clinic.IDEXX news archive as of 04/2026 Because many veterinary practices rely on IDEXX systems for day?to?day diagnostics, switching costs can be meaningful, reinforcing the durability of these revenue streams.

Industry trends and competitive position

The global pet care market has seen sustained growth in recent years, with rising pet ownership and a trend toward treating companion animals as family members, which supports higher spending on veterinary care, according to industry research from several market intelligence firms cited by IDEXX in its investor presentations.IDEXX investor presentation as of 03/2026 This structural backdrop has helped diagnostics providers like IDEXX grow faster than general healthcare markets.

IDEXX competes with other diagnostic and animal health companies in areas such as in?clinic analyzers, point?of?care testing and laboratory services, but the company has emphasized its focus on innovation and its integrated offering of instruments, consumables, labs and software as competitive differentiators.IDEXX strategic overview as of 10/2025 Management has also pointed to its large installed base of analyzers as a key asset, as it creates a long runway for recurring consumable sales.

On the capital markets side, IDEXX shares feature prominently in some thematic and ESG?focused US exchange?traded funds, underlining the stock’s relevance for both growth and sustainability?oriented investors.Nuveen fund holdings as of 12/2025 Such inclusion can support demand from institutional investors, although flows may also amplify volatility in periods of sector rotation.

Why IDEXX Laboratories matters for US investors

For US investors, IDEXX Laboratories represents an established player in the growing field of veterinary diagnostics, listed on the Nasdaq Global Select Market and therefore easily accessible via US brokers and retirement accounts.MarketBeat company overview as of 06/2026 The stock offers exposure to long?term trends in pet humanization, preventive care and the increasing role of data and diagnostics in veterinary medicine.

The company’s revenue is diversified across the United States, Europe and other international regions, but North America remains a key profit engine, meaning that IDEXX’s performance is closely linked to the health of the US consumer and pet care economy.IDEXX annual report as of 02/2025 As a member of major US indices and a component in multiple growth?oriented ETFs, IDEXX can also be sensitive to broader movements in US equity markets and interest rate expectations.

Because the business model leans heavily on recurring diagnostic and software revenues rather than one?time drug launches, some investors view IDEXX as a way to gain health?care?adjacent exposure that is less tied to traditional pharmaceutical pipelines.Seeking Alpha company overview as of 05/2026 At the same time, the high valuation commonly afforded to the shares means that sentiment and expectations around growth trajectories can have a pronounced impact on short?term stock performance.

Conclusion

IDEXX Laboratories has drawn renewed market attention after a strong quarterly report that combined double?digit companion animal revenue growth with earnings ahead of expectations and a noticeable share price move within the Nasdaq 100. The company’s focus on recurring diagnostics and software revenue, supported by structural growth in pet health spending, stands out as a central element of its equity story. At the same time, the stock’s performance remains sensitive to broader market conditions, valuation debates and ongoing execution in expanding its analyzer base and test menu.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.